Results 181 to 190 of about 49,566 (218)

Efficacy of NAs in combination with Peg-IFN for functional cure in patients with CHB: a meta-analysis of RCTs. [PDF]

Ann Med
Zhang Y, Zhang Z, Li X, Cao W, Wang S, Deng W, Wei X, Yao L, Xie Y, Li M.   +9 more
europepmc   +1 more source

Retrospective analysis of adverse pregnancy outcomes associated with hepatitis B virus infection. [PDF]

BMC Pregnancy Childbirth
Cong J, Guo Y, Yi W.
europepmc   +1 more source

Clinical value of serum HBV RNA in patients with chronic hepatitis B during antiviral therapy. [PDF]

PeerJ
Zhang X, Lu F, Wu R, Jin Q, Zhou Y, Wang C, Shao H, Liu S.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B.

Journal of Hepatology, 2023
BACKGROUND & AIMS Nucleos(t)ide analogues (NUCs) are the standard and mostly lifelong treatment for chronic HBeAg-negative hepatitis B, as functional cure (loss of HBsAg) is rarely achieved.
F. van Boemmel, K. Stein, R. Heyne, J. Petersen, P. Buggisch, C. Berg, S. Zeuzem, A. Stallmach, M. Sprinzl, E. Schott, A. Pathil-Warth, U. von Arnim, V. Keitel, J. Lohmeyer, K. Simon, C. Trautwein, A. Trein, D. Hüppe, M. Cornberg, F. Lammert, P. Ingiliz, R. Zachoval, H. Hinrichsen, A. Zipprich, H. Klinker, J. Schulze zur Wiesch, A. Schmiedeknecht, O. Brosteanu, T. Berg   +28 more
semanticscholar   +1 more source

Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis

Gut, 2021
Background and aims Sustained virological suppression and hepatitis B surface antigen (HBsAg) loss have been described after nucleot(s)ide analogue (NA) discontinuation for patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB ...
S. Hall, Sara Vogrin, Olivia Wawryk, G. Burns, K. Visvanathan, V. Sundararajan, A. Thompson   +6 more
semanticscholar   +1 more source

Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B

New England Journal of Medicine, 2005
Florian van Bömmel, Satawat Thongsawat, Edward Gane   +2 more
exaly   +2 more sources

A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B

New England Journal of Medicine, 2006
Ting-Tsung Chang, Kwang-Hyub Han, Zachary Goodman   +2 more
exaly   +2 more sources

Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial

The Lancet Gastroenterology and Hepatology, 2016
Maria Buti, Edward Gane, Wan-Long Chuang
exaly   +2 more sources

Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients – FINITE study

Journal of Hepatology, 2017
Thomas Berg, Karl-Georg Simon, Markus Cornberg   +2 more
exaly   +2 more sources